|
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 1085-1093.
Prepublished online as a Blood First Edition Paper on September 23, 2004; DOI 10.1182/blood-2004-03-1101.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin
James T. B. Crawley,
Jonathan K. Lam,
James B. Rance,
Luigina R. Mollica,
James S. O'Donnell, and
David A. Lane
From the Haematology Department, Division of Investigative Sciences, Faculty of Medicine, Imperial College London, United Kingdom.
The multimeric size and the function of circulating von Willebrand factor are modulated via its proteolytic cleavage by the plasma metalloproteinase, ADAMTS13. It is unclear how ADAMTS13 activity is regulated within the vascular system. In the absence of a regulatory mechanism, ADAMTS13 activity might compromise platelet adhesion at sites of vascular injury. We hypothesized that at sites of vascular injury, ADAMTS13 activity could be regulated locally by coagulation proteinases. Initiation of coagulation in human plasma resulted in the disappearance of added full-length recombinant ADAMTS13. This loss was inhibited by hirudin. Using purified proteins, we showed that ADAMTS13 is proteolyzed at several cleavage sites by thrombin in a time- and concentration-dependent manner. Furthermore, this proteolysis ablated ADAMTS13 activity against purified von Willebrand factor. Preincubation of thrombin with soluble thrombomodulin, but not heparin, inhibited the proteolysis of ADAMTS13, suggesting the involvement of thrombin exosite I (and not exosite II) in ADAMTS13 recognition. Plasmin also cleaved ADAMTS13 into similar fragments, resulting in the loss of ADAMTS13 activity. This study demonstrates the susceptibility of ADAMTS13 to proteolytic inactivation and suggests possible roles for thrombin and plasmin at sites of vascular injury.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Down-regulation of ADAMTS13 activity by serine proteases
- Yoshihiro Fujimura
Blood 2005 105: 911-912.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
B. Ponnuchamy and R. A. Khalil
Role of ADAMs in Endothelial Cell Permeability: Cadherin Shedding and Leukocyte Rolling
Circ. Res.,
May 23, 2008;
102(10):
1139 - 1142.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Chung, T. G. Popova, S. C. Jorgensen, L. Dong, V. Chandhoke, C. L. Bailey, and S. G. Popov
Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy
J. Biol. Chem.,
April 11, 2008;
283(15):
9531 - 9542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Swisher, J. T. Doan, S. K. Vesely, H. C. Kwaan, B. Kim, B. Lammle, J. A. Kremer Hovinga, and J. N. George
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports
Haematologica,
July 1, 2007;
92(7):
936 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ferrari, F. Scheiflinger, M. Rieger, G. Mudde, M. Wolf, P. Coppo, J.-P. Girma, E. Azoulay, C. Brun-Buisson, F. Fakhouri, et al.
Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity
Blood,
April 1, 2007;
109(7):
2815 - 2822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. N. K. Chion, C. J. M. Doggen, J. T. B. Crawley, D. A. Lane, and F. R. Rosendaal
ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men
Blood,
March 1, 2007;
109(5):
1998 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Nguyen, A. Liu, L. Liu, C. Ball, H. Choi, W. S. May, K. Aboulfatova, A. L. Bergeron, and J.-f. Dong
Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis
Haematologica,
January 1, 2007;
92(1):
121 - 124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Guinto, N. Grafos, D. G. Motto, and R. S. Greenfield
Recombinant ADAMTS13 Processing by FXIa Is Distinct from Thrombin.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
4041 - 4041.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. E. Adams and J. A. Huntington
Thrombin-Cofactor Interactions: Structural Insights Into Regulatory Mechanisms
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2006;
26(8):
1738 - 1745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Chauhan, D. G. Motto, C. B. Lamb, W. Bergmeier, M. Dockal, B. Plaimauer, F. Scheiflinger, D. Ginsburg, and D. D. Wagner
Systemic antithrombotic effects of ADAMTS13
J. Exp. Med.,
March 20, 2006;
203(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zanardelli, J. T. B. Crawley, C. K. N. C. K. Chion, J. K. Lam, R. J. S. Preston, and D. A. Lane
ADAMTS13 Substrate Recognition of von Willebrand Factor A2 Domain
J. Biol. Chem.,
January 20, 2006;
281(3):
1555 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ono, J. Mimuro, S. Madoiwa, K. Soejima, Y. Kashiwakura, A. Ishiwata, K. Takano, T. Ohmori, and Y. Sakata
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure
Blood,
January 15, 2006;
107(2):
528 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Lane, H. Philippou, and J. A. Huntington
Directing thrombin
Blood,
October 15, 2005;
106(8):
2605 - 2612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. O'Donnell, T. A. J. McKinnon, J. T. B. Crawley, D. A. Lane, and M. A. Laffan
Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis
Blood,
September 15, 2005;
106(6):
1988 - 1991.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
